Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive

  title={Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive},
  author={Leo Han and Jeffrey T. Jensen},
  journal={Expert Opinion on Pharmacotherapy},
  pages={2071 - 2079}
  • Leo HanJ. Jensen
  • Published 9 September 2014
  • Medicine
  • Expert Opinion on Pharmacotherapy
Introduction: Oral contraceptives are often prescribed in extended or continuous forms in order to manage menstrual bleeding and menstrual-related side effects. However, with extended regimens, unscheduled intracycle bleeding can become problematic. Flexible extended dosing of a contraceptive containing drospirenone (DRSP) and ethinyl estradiol (EE) was designed to improve bleeding profiles during extended cycles through active management of bleeding symptoms. Areas covered: We examine the… 

Advances in pharmacotherapy for treating endometriosis

The treatments most recently proposed for endometriosis will be described in detail, including gonadotropin-releasing hormone (GnRH) antagonists, aromatase inhibitors (AIs) and the flexible extended combined oral contraceptive.

Sexuality and Disability in Adolescents.

Regulation of Cervical Mucus Secretion

Sexuality and Disabil ity in Adolescents

When caring for adolescents, providers may feel ill equipped to address issues of sexuality. In part, this may reflect the tendency to equate “sexuality” with “sexual intercourse.” Sexual development



Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study

The flexibleMIB regimen allows women to extend their menstrual cycle and manage their intracyclic (breakthrough) bleeding and is associated with statistically significantly fewer bleeding/spotting days and fewer withdrawal bleeding episodes vs EE/DRSP in a conventional 28-day regimen.

Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study

EE/DRSP in a flexible extended regimen with management of intracyclic (breakthrough) bleeding is well-tolerated and, when administered for up to 2 years, has a good safety profile comparable to other estrogen/progestogen oral contraceptives.

Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.

The treatment was well tolerated with an excellent safety profile and the majority of women (86%) stated that they were satisfied or very satisfied with the treatment and over 70% of women would have continued with the study medication.

A multicenter, randomized study of an extended cycle oral contraceptive.

Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study

Extending the established 24/4-day regimen of EE 20 µg/DRSP 3 mg does not change the known steady-state PK of EE and DRSP, suggesting that the clinical efficacy is also similar, in line with the published clinical results from this study.